The Nomination Committee of Getinge AB (publ) has decided to propose to the Annual General Meeting 2026 that the Meeting elects Camilla Sylvest as a new member of the Board of Directors. The Nomination Committee also informs that the current Board member Malin Persson, who has served since 2014, has announced that she will not be available for re-election in 2026.
Camilla Sylvest has more than 28 years of experience at Novo Nordisk A/S, most recently serving eight years as Executive Vice President, Commercial Strategy and Corporate Affairs, and as a member of the executive management team. She led global commercial strategy across diabetes, obesity, and cardiovascular disease and the global launches of Ozempic and Wegovy. Previously she held General Manager roles for Novo Nordisk affiliates in Denmark, Germany, Southeast Asia, and Region China. She currently serves on the board of directors of argenx SE, a global biotechnology company, headquartered in the Netherlands.
In connection with the notice to the Annual General Meeting 2026, the Nomination Committee's complete proposal together with a reasoned statement will be made available.
Contact for the Nomination Committee:
Carl Bennet
Chairman of the Nomination Committee
Phone +46 705 684 477
Contact:
David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.